Title : Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.

Pub. Date : 2016 Oct

PMID : 27266804






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 This phase 2 study evaluated the efficacy of trabectedin at a dose of 1.3 mg/m2 as a 3-hour intravenous infusion every 3 weeks in hormone receptor-positive, HER-2 (human epidermal growth factor receptor 2)-negative, advanced breast cancer patients according to the tumor level of XPG mRNA expression. Trabectedin ERCC excision repair 5, endonuclease Homo sapiens